BTX-6654 formate
Based on 1 Customer Validation
BTX-6654 formate is a SOS1 PROTAC degrader. BTX-6654 formate induces ubiquitination and degradation of SOS1 via the proteasomal pathway by bridging SOS1 with the E3 ligase CRBN to form a ternary complex, thereby blocking KRAS activation and downregulating the MAPK signaling pathway (pERK/pS6), and ultimately inhibiting tumor growth. BTX-6654 formate can be used in research on various cancers driven by KRAS mutations.
(Pink: SOS1 ligand (HY-175896); Blue: Cereblon ligand (HY-138881); Black: linker).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 98.85%
- 分子式: C51H59F4N9O7
- 分子量:986.06
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
PROTACs アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
体外実験
BTX-6654 potently and specifically degrades SOS1 in KRAS-mutant cancer cells, with a DC50 value of < 11 nM; it also inhibits the downstream pERK and pS6 signaling pathways, with corresponding IC50 values of 1-32 nM and 4-22 nM, respectively[1].
BTX-6654 potently inhibits the viability of specific human cancer cell lines (including MIA PaCa-2, A549, NCI-H1975 and SNU-175), with IC50 values as low as 1.2 nM, but shows no significant activity against many other cancer cell lines with specific KRAS, NRAS, BRAF, NF1 mutations or KRAS deletion status (IC50 >2500 nM)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MIA PaCa-2, LoVo
-
Concentration:50, 200 nM
-
Incubation Time:1, 2, 4, 6 h
-
Result:Resulted in time-dependent, maximal degradation of SOS1 within 6 hours.
-
Cell Line:MIA PaCa-2, LoVo
-
Concentration:50, 200 nmol/L (+ CC-220, MG132 or MLN4924)
-
Incubation Time:6 h
-
Result:Induced degradation of SOS1 was completely blocked by the CRBN ligand or proteasome/NEDD8 inhibitors.
-
Cell Line:MIA PaCa-2 (3D)
-
Concentration:0.8, 4, 20, 100, 500 nM
-
Incubation Time:24 h
-
Result:Significantly inhibited the downstream phosphorylation of pERK and pS6.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude mice (6-8 weeks old, female) were subcutaneously inoculated with NCI-H358 cells in the right flank[1]
-
Dosage:10, 50 mg/kg
-
Administration:i.p.; single dose; 2, 8, 24 h
-
Result:Downregulated SOS1 and pERK proteins in histology.
-
Animal Model:BALB/c nude mice (6-8 weeks old, female) were subcutaneously inoculated with NCI-H358 cells or MIA PaCa-2 cells in the right flank[1]
-
Dosage:2, 10 mg/kg
-
Administration:i.p.; twice daily; 28 days
-
Result:Inhibited tumor growth in a dose-dependent manner.
No significant effect on animal body weight.
-
Animal Model:BALB/c nude mice (6-8 weeks old, female) were subcutaneously inoculated with xMIA PaCa-2 cells in the right flank[1]
-
Dosage:10 mg/kg (+ 10 mg/kg Sotorasib or 0.125 mg/kg Trametinib)
-
Administration:i.p.; twice daily; 30 days
-
Result:A trend toward profound tumor regression was observed in the combination therapy group.
化学情報
-
性状 Solid
-
分子量 986.06
-
分子式 C51H59F4N9O7
-
Color White to off-white
-
SMILES
FC(F)(F)C1=C(C)C([C@@H](C)NC2=NN=C(C)C3=CC=C(N4CCN(C(C5CCN(C(CCN6CCC(C7=CC(CN(C8CCC(NC8=O)=O)C9=O)=C9C=C7F)CC6)=O)CC5)=O)CC4)C=C32)=CC=C1.O=CO
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
溶剤 & 溶解度
体外:
DMSO : 100 mg/mL (101.41 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
体内:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.54 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (2.54 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
プロトコル
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
純度とドキュメンテーション
-
データシート (281 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.0141 mL | 5.0707 mL | 10.1414 mL | 25.3534 mL |
| 5 mM | 0.2028 mL | 1.0141 mL | 2.0283 mL | 5.0707 mL | |
| 10 mM | 0.1014 mL | 0.5071 mL | 1.0141 mL | 2.5353 mL | |
| 15 mM | 0.0676 mL | 0.3380 mL | 0.6761 mL | 1.6902 mL | |
| 20 mM | 0.0507 mL | 0.2535 mL | 0.5071 mL | 1.2677 mL | |
| 25 mM | 0.0406 mL | 0.2028 mL | 0.4057 mL | 1.0141 mL | |
| 30 mM | 0.0338 mL | 0.1690 mL | 0.3380 mL | 0.8451 mL | |
| 40 mM | 0.0254 mL | 0.1268 mL | 0.2535 mL | 0.6338 mL | |
| 50 mM | 0.0203 mL | 0.1014 mL | 0.2028 mL | 0.5071 mL | |
| 60 mM | 0.0169 mL | 0.0845 mL | 0.1690 mL | 0.4226 mL | |
| 80 mM | 0.0127 mL | 0.0634 mL | 0.1268 mL | 0.3169 mL | |
| 100 mM | 0.0101 mL | 0.0507 mL | 0.1014 mL | 0.2535 mL |
BTX-6654 formate 関連分類
HY-161233A 関連分類
Powered by Bioz